Satsuma Pharmaceuticals, a subsidiary of Shin Nippon Biomedical Laboratories (TYO:2395), has secured US FDA approval for Atzumi (dihydroergotamine nasal powder) to treat acute migraines in adults, according to a Thursday filing on the Tokyo Stock Exchange.
Developed using Shin Nippon Biomedical's unique intranasal delivery platform, Atzumi is the first FDA-approved nasal migraine treatment. The approval follows successful Phase 1 and Phase 3 trials.
Price (JPY): $1562.00, Change: $-3.0, Percent Change: -0.19%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.